These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7683360)

  • 1. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
    De Clercq E
    Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
    J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
    Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of the acquired immune deficiency syndrome (AIDS): non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase.
    De Clercq E
    Int J Immunopharmacol; 1991; 13 Suppl 1():83-9. PubMed ID: 1726686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
    Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
    Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
    J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
    Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.
    Debyser Z; De Vreese K; Pauwels R; Yamamoto N; Anné J; De Clercq E; Desmyter J
    J Gen Virol; 1992 Jul; 73 ( Pt 7)():1799-804. PubMed ID: 1378481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Vrang L; Walbers J; Zhang H; Oberg B; Vandamme AM; Camarasa MJ; De Clercq E
    Virology; 1993 Jan; 192(1):246-53. PubMed ID: 7685964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Balzarini J; Karlsson A; De Clercq E
    Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
    Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
    Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
    J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.